The digital health IPO window reopened in 2025, and it is real. It is also not the window that late-2010s founders were promised, and confusing the two will cost a board a lot of misdirected planning time.

Hinge Health closed its first day of trading in May 2025 up about 17 percent from its $32 IPO price, a genuinely good public debut by market standards. TechCrunch's framing of that same event is the part worth sitting with: Hinge joined "growing ranks of down-round IPOs," pricing well below its last private valuation. Omada Health went public in the same window, and both CEOs later appeared together at HLTH to discuss what Healthcare Dive described as an open window clouded by uncertainty.

That is the pattern to plan around: the window is open for revenue-scale, evidence-backed companies, and it is pricing them at a real discount to their last private mark.

Why the public market is repricing digital health, specifically

A structural analysis of the 2026-2027 digital health IPO landscape frames this as a valuation reset rather than a closed market, and lays out the paradox directly: there is a large backlog of venture-backed digital health companies that need a liquidity path, and the public market that is theoretically open to them is only rewarding a specific profile.

Noah Intelligence's reporting on the shift names that profile precisely: public investors in 2026 are favoring companies with proven recurring revenue, demonstrated clinical utility, and tangible productivity gains, and rotating away from growth-at-any-cost narratives that defined the 2020 and 2021 cohort.

What separates a company that IPOs well from one that gets down-rounded on the way out

  • Recurring, contracted revenue with visible renewal behavior, not bookings that convert unevenly.
  • Clinical or outcomes evidence that a public-market analyst without a medical background can still verify, typically published or third-party validated, not solely internally generated.
  • A path to demonstrable operating leverage, because public investors are pricing in the cost of capital environment, not the 2021 assumption that growth alone justifies the multiple.
  • A last private round priced with enough discipline that the IPO does not require a public down-round to clear the market. This is the single biggest lesson from the 2025 cohort: companies that raised late private rounds at aggressive marks walked into their IPO already priced above what public investors were willing to pay.

The IPO candidate profile checklist

A candidate-profile breakdown of the digital health IPO pipeline lays out the realistic bar for the next wave. In practice, boards evaluating an IPO path in the next 18 months should be testing for:

  1. Multiple consecutive quarters of revenue growth with a visible, explainable deceleration curve rather than an unexplained spike.
  2. Gross margin in the range public software and healthcare-services investors already understand, without a story required to justify it.
  3. A regulatory or evidence position that survives scrutiny from analysts who will not take a vendor's clinical claims at face value.
  4. A last private mark that a public buyer can actually clear, tested against real public comparables, not against the last funding cycle's comparable set.

What this means for boards planning an exit timeline

The mistake I see boards make is treating "the window is open" as license to run the same playbook that worked in 2019, timed for a different calendar year. The window is open for a narrower company profile than it was then, and it is actively punishing companies that raised late-stage private capital at valuations the public market will not honor.

If your last private round priced you meaningfully above what a realistic public comparable set would support, the correct sequence is not to wait for the window to widen. It is to grow into the valuation you already have, through revenue and margin, before you go public into it. The alternative is what happened to a chunk of the 2025 IPO cohort: a good first trading day on a price that was already a markdown from where private investors last valued the company.